Protagonist Therapeutics Inc
NASDAQ:PTGX
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
17.42
48.43
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Protagonist Therapeutics Inc
Protagonist Therapeutics Inc
Change in Working Capital
Protagonist Therapeutics Inc
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Protagonist Therapeutics Inc
NASDAQ:PTGX
|
Change in Working Capital
$28.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Change in Working Capital
-$1.9B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-20%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Change in Working Capital
$7.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Change in Working Capital
-$612m
|
CAGR 3-Years
30%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Change in Working Capital
-$793.5m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Change in Working Capital
-$593.3m
|
CAGR 3-Years
28%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
Protagonist Therapeutics Inc
Glance View
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. The company is headquartered in Newark California, California and currently employs 118 full-time employees. The company went IPO on 2016-08-11. The firm uses its peptide technology platform to discover and develop peptide-based drugs to address unmet medical needs. Its clinical programs address two categories of diseases, which includes hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the treatment of erythrocytosis, iron overload and other blood disorders. The Company’s alpha-4-beta-7 (α4β7) antagonist PN-943 and its Interleukin-23 receptor (IL-23R) antagonist compound PN-235 are orally delivered investigational drugs that are designed to block biological pathways. PN-943 is an investigational, orally delivered, gut-restricted α4β7 specific integrin antagonist for inflammatory bowel disease (IBD). Its PN-235 is an orally delivered IL-23R specific antagonist for the treatment of IBD and non-IBD indications.
See Also
What is Protagonist Therapeutics Inc's Change in Working Capital?
Change in Working Capital
28.7m
USD
Based on the financial report for Sep 30, 2024, Protagonist Therapeutics Inc's Change in Working Capital amounts to 28.7m USD.
What is Protagonist Therapeutics Inc's Change in Working Capital growth rate?
Change in Working Capital CAGR 5Y
0%
You don't have any saved screeners yet
